Enlivex Therapeutics Ltd

+0.09 (+0.82%)
Products, Regulatory, Community

Enlivex Says Israeli Ministry Of Health Authorizes Initiation Of Phase IIb Clinical Trial Evaluating Allocetra In Severe COVID-19 Patients

Published: 08/15/2021 10:12 GMT
Enlivex Therapeutics Ltd (ENLV) - Enlivex Therapeutics - Israeli Ministry of Health Authorizes Initiation of Phase Iib Clinical Trial Evaluating Allocetra in Severe Covid-19 Patients.
Enlivex -phase Iib Trial Expected to Recruit Up to 152 Severe Or Critical Covid-19 Patients in Clinical Centers in Israel & Certain European Countries.
Enlivex Therapeutics Ltd - Trial to Assess Safety and Efficacy of Allocetratm When Administered in Addition to Standard of Care Treatment.
Enlivex- Trial Will Have Two Primary Endpoints: Ventilation-free Survival and Recovery for Each of Two Sub-populations of Patients in Study.
Enlivex Therapeutics Ltd - Trial Will Assess Several Secondary Endpoints, Including Evaluation of Long-covid-19 Symptoms.